v3.26.1
Revenue - Additional Information (Details)
 3 Months Ended
Jul. 01, 2025
USD ($)
Mar. 31, 2026
USD ($)
Milestones
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
May 13, 2025
Disaggregation of Revenue [Line Items]          
Service revenue   $ 26,523,000 $ 219,000    
Novo Collaboration Agreement          
Disaggregation of Revenue [Line Items]          
Percentage of reimbursement         100.00%
Number of milestones probable to achievement | Milestones   2      
Number of discovery research milestones probable to achievement | Milestones   2      
Probable milestone payments   $ 2,000,000      
Service revenue [1]   71,900,000      
One-time non-refundable upfront payment paid $ 195,000,000        
Allowance for credit loss   0   $ 0  
Novo Collaboration Agreement | Maximum          
Disaggregation of Revenue [Line Items]          
Milestone payments receivable from collaboration agreement   $ 498,000,000      
[1] For the three months ended March 31, 2026, the Company recognized revenue of $26.5 million, which was comprised of $10.3 million variable consideration related to research services for the four R&D Programs and manufacturing services, $15.7 million recognition of deferred revenue for the one-time, non-refundable upfront payment, and $0.5 million milestone revenue recognized on the two milestones discussed above. The Company recognized $26.8 million of the one-time, non-refundable upfront payment and $18.6 million variable considerations related to research services for the four R&D Programs and manufacturing services during the year ended December 31, 2025.